C3 and neurodevelopmental disorder: While preclinical studies have suggested that targeting components of the complement system, such as C3 [25, 26] or C1q, may be relevant for the treatment of neurodevelopmental disorders, there are presently no registered clinical trials examining the efficacy of drugs that target the complement system for any identified neurodevelopmental disorder.